List of Excipients in Branded Drug GENTLELAX

Generic Drugs Containing GENTLELAX

Company	Ingredient	NDC	Excipient
Kroger Company	polyethylene glycol 3350	30142-504	SUCRALOSE

What are the Most Frequently-Used Excipients in GENTLELAX?

# Of NDCs	Excipient
1	SUCRALOSE

GENTLELAX Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 19, 2026

GentleLax is an over-the-counter polyethylene glycol 3350 laxative product. Its commercial position depends less on patent exclusivity than on compliant formulation, consumer trust, retail distribution, packaging, price, and dosing convenience. The core powder formula has limited excipient differentiation because PEG 3350 products are commonly sold as single-ingredient, unflavored powders with no listed inactive ingredients.

What is GentleLax and how does its formulation work?

GentleLax is marketed as an osmotic laxative containing polyethylene glycol 3350, commonly abbreviated PEG 3350. The standard adult dose is 17 grams dissolved in 4 to 8 ounces of liquid and taken once daily, consistent with the FDA monograph framework for osmotic laxative products.[1]

Attribute	GentleLax commercial profile
Active ingredient	Polyethylene glycol 3350
Dosage form	Oral powder for solution
Typical dose	17 grams once daily
Therapeutic category	Osmotic laxative
Primary use	Occasional constipation
Typical age labeling	Adults and children 17 years and older, unless directed by a physician
Prescription status	OTC
Formulation complexity	Low
Primary differentiation	Price, packaging, flavor, dosing, retail access, and brand recognition

PEG 3350 works by retaining water in the stool. It is chemically distinct from stimulant laxatives such as bisacodyl and senna and from bulk-forming products such as psyllium.

What excipients are used in GentleLax?

The core product is generally positioned as an unflavored PEG 3350 powder. Public product labeling for PEG 3350 laxative powders commonly identifies no inactive ingredients or uses only limited processing and packaging components that do not appear as formulation excipients in the consumer label.[2]

This creates a narrow but commercially useful excipient strategy:

1. Preserve an essentially single-ingredient, unflavored formulation.
2. Develop flavored versions with a controlled sweetener, acidulant, and flavor system.
3. Improve powder handling through particle-size control, flow aids, and moisture-barrier packaging.
4. Create premeasured sachets or stick packs that reduce dosing errors.
5. Develop pediatric or caregiver-oriented formats only within applicable FDA labeling and safety requirements.

The primary formulation risk is not complex excipient compatibility. It is maintaining rapid dispersion, acceptable mouthfeel after dissolution, dose uniformity, and stable product performance during storage.

What excipient opportunities exist for GentleLax?

The strongest commercial opportunity is a line extension rather than a reformulation of the core product.

Flavor systems

Unflavored PEG 3350 has a neutral consumer profile, but some users perceive mild texture or residual taste after mixing. Flavor systems could support:

• Lemon-lime
• Berry
• Orange
• Fruit punch
• Unflavored versions for coffee, water, or juice

Flavoring must not materially reduce consumer flexibility. A product designed to dissolve in multiple beverages can lose utility if the flavor is too strong or incompatible with milk, carbonated drinks, or hot beverages.

Potential excipients include:

Excipient class	Commercial purpose	Key technical issue
Natural or synthetic flavor	Improve palatability	Flavor stability and beverage compatibility
Sucralose, stevia, or other sweetener	Reduce bitterness or improve taste	Aftertaste and consumer acceptance
Citric acid or citrate buffer	Control flavor profile and pH	Stability and sensory intensity
Silicon dioxide or similar flow aid	Improve powder handling	Dusting, regulatory status, and label disclosure
Maltodextrin or carrier	Support flavor dispersion	Added calories and ingredient-list complexity

The commercial case for flavoring is strongest where consumers are taking PEG 3350 repeatedly and where the product competes with flavored powders, gummies, liquid laxatives, or combination digestive-health products.

Premeasured dose packaging

A 17-gram stick pack can convert a commodity powder into a convenience product. Advantages include:

• Reduced measuring errors
• Better portability
• Easier pharmacy counseling
• Improved adherence
• More attractive e-commerce packaging
• Potential use in travel and workplace settings

The principal risk is packaging cost. A bottle with a measuring cap has a lower unit-cost structure than individually packaged sachets. Premium stick packs therefore require a clear retail price premium or higher repeat purchase rate.

Pediatric and caregiver formats

PEG 3350 is widely used in pediatric practice, but OTC labeling, dosing instructions, age statements, and safety claims require careful regulatory control. A pediatric commercial program could use:

• Smaller premeasured doses
• Low-dust sachets
• Flavor systems
• Color-coded dosing tools
• Caregiver-focused instructions

A pediatric product should not rely solely on a smaller packet. The formulation, dose presentation, claims, and labeling would need to align with FDA requirements and the relevant clinical evidence.

Liquid concentrate and ready-to-drink products

Liquid formats could improve convenience but would create more technical and economic complexity. A liquid PEG 3350 product would require evaluation of:

• Viscosity
• Preservative strategy
• Microbial control
• Container compatibility
• Chemical stability
• Shipping weight
• Taste masking
• Dose uniformity

The higher manufacturing cost and logistics burden make liquid products less attractive than dry powder sachets unless the target segment has a strong willingness to pay.

What patents protect GentleLax?

The core PEG 3350 product is unlikely to have meaningful composition-of-matter exclusivity. PEG 3350 is a longstanding polymer used in pharmaceutical and nonpharmaceutical applications. The commercial product is generally protected through trademarks, packaging, manufacturing know-how, supply agreements, and retail placement rather than a broad active-ingredient patent.

IP category	Relevance to GentleLax
Composition-of-matter patent	Low relevance for PEG 3350
Formulation patent	Possible for flavor, dispersion, stability, or dosage presentation
Method-of-use patent	Limited for ordinary OTC constipation treatment
Packaging patent	Possible for specialized sachets, dosing systems, or moisture barriers
Trademark	Important for brand recognition
Trade secret	Relevant to sourcing, particle size, blending, flavor systems, and packaging
Regulatory exclusivity	Limited compared with prescription drugs

Any patent opportunity would likely focus on a specific product architecture, such as a stable flavored PEG 3350 powder, a low-dust premeasured dose, a child-resistant dispensing system, or a combination product.

A formulation patent must provide a real technical distinction. Merely adding a conventional flavor or sweetener to PEG 3350 may face novelty, obviousness, and enablement challenges. Stronger claims would require measurable performance advantages, such as improved dissolution, reduced clumping, enhanced stability, or a defined sensory profile supported by comparative data.

When does GentleLax lose exclusivity?

GentleLax does not follow the standard prescription-drug exclusivity model. OTC laxative products that comply with the applicable FDA monograph can be marketed without an innovator NDA monopoly comparable to a prescription product.[1]

Orange Book status

GentleLax is not expected to have the type of Orange Book patent listing associated with an NDA-approved prescription drug. The Orange Book primarily identifies approved drug products and patent or exclusivity information relevant to abbreviated new drug applications.[3]

For a monograph-compliant OTC PEG 3350 product:

• An Orange Book patent listing is generally not the principal commercial barrier.
• A Paragraph IV challenge is generally not the applicable generic-entry mechanism.
• Market entry depends on monograph compliance, drug establishment requirements, labeling, quality systems, and distribution.
• Trademark and trade dress can remain important after competing products enter.

Paragraph IV challenges

A Paragraph IV certification is associated with an ANDA applicant challenging patents listed for an NDA product. It is not the normal pathway for an OTC monograph product such as a standard PEG 3350 laxative.[3]

Competitive entry can therefore occur through multiple manufacturers and private-label retailers without a patent litigation event involving GentleLax.

What FDA regulatory requirements affect GentleLax?

The main regulatory pathway is OTC compliance. FDA monograph requirements cover the active ingredient, dosage, indications, warnings, directions, and labeling format for relevant laxative products.[1]

Key regulatory issues include:

• Use of PEG 3350 at the permitted dosage
• Drug Facts labeling
• Constipation-related indications
• Warnings regarding abdominal pain, nausea, vomiting, bleeding, and prolonged use
• Age-specific directions
• Manufacturing under current good manufacturing practices
• Identity, strength, quality, and purity testing
• Appropriate container-closure systems
• Accurate net quantity and dosing information

A flavored or premium product may remain within the OTC monograph if flavoring changes only palatability and does not alter the active ingredient, dosage, indication, or route of administration. A product making new therapeutic claims could require a different regulatory analysis.

How strong is the GentleLax patent estate?

The patent estate is likely weak for the base product and potentially moderate for narrowly defined delivery or formulation improvements.

Protection layer	Estimated strength	Reason
PEG 3350 active ingredient	Low	Mature, widely used ingredient
Basic unflavored powder	Low	Commodity-like dosage form
Flavored powder	Low to moderate	Patentability depends on technical performance
Premeasured sachet	Moderate	Packaging and dosing claims may be available
Pediatric delivery system	Moderate	Could support differentiated usability and dosing
Manufacturing process	Moderate	Trade secret protection may exceed patent value
Brand and trade dress	Moderate to strong commercially	Consumer recognition and retailer placement
Regulatory barrier	Low to moderate	OTC monograph access supports rapid competition

The most defensible commercial moat is likely a combined strategy involving trademark, distinctive packaging, controlled manufacturing specifications, retailer exclusivity, and a differentiated product format.

Which companies are challenging GentleLax?

GentleLax competes with established PEG 3350 brands, retailer private labels, and generic-equivalent products. The relevant competitive set includes MiraLAX, store-brand PEG 3350 products, and other OTC osmotic laxatives.

Competitor group	Competitive advantage
MiraLAX	High brand recognition and physician familiarity
Store-brand PEG 3350	Lower price and retailer shelf access
Generic drug manufacturers	Manufacturing scale and pharmacy distribution
Fiber products	Natural-product positioning and daily wellness appeal
Stimulant laxatives	Faster perceived onset and low price
Liquid and chewable products	Convenience and palatability

GentleLax can compete most effectively in price-sensitive retail channels, private-label programs, e-commerce bundles, and value-oriented pharmacy distribution.

What commercial opportunities exist for GentleLax?

The highest-value opportunities are incremental and packaging-led.

Private-label and retailer partnerships

PEG 3350 is suitable for retailer brands because the active ingredient and dosage form are standardized. Opportunities include:

• Pharmacy private labels
• Grocery and mass-market retailers
• Club-store multipacks
• E-commerce subscription bundles
• Hospital and long-term-care supply contracts

A private-label model can increase volume but may compress gross margin. Exclusive packaging, retailer-specific flavors, or multipack formats can reduce direct price comparison.

Premium convenience formats

The strongest premium proposition is a portable premeasured dose. A 14- or 30-count stick-pack product could target frequent users, travelers, caregivers, and consumers who dislike measuring powder.

Potential commercial formats include:

• 17-gram sachets
• Multi-flavor variety packs
• Single-serve travel cartons
• Moisture-resistant unit-dose packs
• Dose packs with dissolvable beverage instructions

Combination digestive-health products

PEG 3350 could be paired commercially with products aimed at broader digestive wellness, although combination products require careful regulatory and safety analysis. Potential categories include fiber, electrolytes, probiotics, and hydration products. The main risk is that adding multiple active ingredients changes the regulatory and clinical profile.

Geographic expansion

The product is most readily scalable in markets that recognize PEG 3350 as an OTC laxative or permit comparable monograph-based products. Geographic expansion must account for:

• Local active-ingredient status
• Country-specific dosage limits
• Label translation
• Pediatric requirements
• Food-versus-drug classification
• Import registration
• Local pharmacopoeial standards
• Packaging and serialization rules

The United States offers a relatively accessible monograph pathway but also has intense price competition. International markets may offer better pricing but greater registration complexity.

What manufacturing and IP barriers exist?

Manufacturing barriers are manageable but not negligible. PEG 3350 is a high-volume, mature material, so supplier qualification and quality consistency are central.

Important technical controls include:

• Molecular-weight distribution
• Moisture content
• Particle-size distribution
• Bulk density
• Flowability
• Dissolution time
• Clump resistance
• Foreign-matter control
• Packaging seal integrity
• Stability under heat and humidity

The main operational risk is moisture uptake. Poor packaging can produce clumping, inaccurate dosing, and poor consumer experience. High-barrier laminates, desiccant strategies, and controlled filling conditions can improve shelf stability.

What litigation and settlement risks affect GentleLax?

The ordinary PEG 3350 OTC market does not create the same Paragraph IV litigation profile as a patented prescription product. The principal legal risks are more likely to involve:

• Trademark infringement
• Trade dress copying
• False or unsupported efficacy claims
• Labeling violations
• Product liability
• Manufacturing deviations
• Advertising claims concerning safety, onset, or pediatric use
• Supply and private-label contract disputes

A formulation or packaging patent could create litigation risk if a competitor copies a genuinely differentiated product. A basic PEG 3350 powder has a substantially weaker litigation position.

What revenue exposure does GentleLax create?

No standalone revenue figure should be inferred from the product name. OTC brands are often sold through private-label, distributor, or retailer arrangements, and manufacturers may not report product-level sales.

Revenue exposure is driven by:

• Retail distribution breadth
• Average selling price
• Repeat-use frequency
• Pack size
• Private-label versus branded mix
• Promotional spending
• PEG 3350 input costs
• Packaging format
• Retailer concentration

A low-cost bottle can generate volume but limited margin. A stick-pack or flavored product can improve gross profit if consumers accept a premium and the packaging cost remains controlled.

Key Takeaways

• GentleLax is a PEG 3350 OTC osmotic laxative with a low-complexity core formulation.
• The strongest excipient strategy is to preserve the single-ingredient powder while developing flavored, premeasured, low-dust, and travel-oriented formats.
• The base product is unlikely to have meaningful composition-of-matter patent protection.
• OTC monograph compliance, not Orange Book exclusivity, is the primary regulatory framework.
• Paragraph IV litigation is generally not the expected competitive-entry mechanism.
• The most valuable commercial moat is a combination of brand, packaging, retail access, supply reliability, and manufacturing specifications.
• Private-label distribution and unit-dose sachets offer the clearest growth paths.
• Biosimilar risk is not applicable because PEG 3350 is a synthetic small-molecule polymer product, not a biologic.
• Manufacturing barriers are moderate and center on powder flow, moisture control, dose uniformity, and packaging integrity.

FAQs About GentleLax Excipient and Commercial Strategy

Can GentleLax be sold without inactive ingredients?

Yes. A PEG 3350 powder can be marketed with no consumer-listed inactive ingredients if the formulation and manufacturing process meet applicable requirements. Packaging materials and processing aids may still be subject to quality controls.

Is flavored PEG 3350 patentable?

Possibly, but a conventional flavor addition may not support a strong patent. A stronger application would need evidence of improved dissolution, stability, taste performance, reduced clumping, or another technical benefit.

Does GentleLax need an ANDA?

A standard OTC monograph-compliant product generally does not require an ANDA in the same manner as an approved prescription drug. The manufacturer must meet applicable FDA OTC, labeling, registration, and current good manufacturing practice requirements.

Is PEG 3350 suitable for a premium supplement product?

PEG 3350 is regulated as a drug active ingredient in relevant laxative products, so repositioning it as a dietary supplement may create classification and labeling problems. A premium drug product with improved packaging and flavor is generally the more direct commercial route.

What is the best GentleLax product extension?

A premeasured 17-gram stick pack with moisture-resistant packaging and optional light flavoring is the most commercially credible extension. It adds convenience without introducing the manufacturing complexity of a liquid product.

References

1. U.S. Food and Drug Administration. (2020). Laxative drug products for over-the-counter human use: Final administrative order, OTC Monograph M007. https://www.fda.gov
2. National Library of Medicine. (n.d.). DailyMed: Polyethylene glycol 3350 powder drug labeling. https://dailymed.nlm.nih.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov